Global Xerostomia Treatments Market Roadmap to 2031

The Xerostomia Treatments market is witnessing significant growth and is expected to expand at a CAGR of 18% during the forecast period from 2023 to 2031. This growth is primarily driven by increasing technological advancements, rising consumer demand, and expanding applications across various industries. Businesses are increasingly adopting innovative solutions to improve operational efficiency, enhance customer experiences, and gain a competitive advantage, further fueling market expansion.

Source: HTF Market Intelligence (HTF MI)

Xerostomia is a condition that leads to the dry mouth caused by the minimal amount or absence of saliva in the mouth. Xerostomia is not viewed as a disease, but rather as a symptom. Xerostomia can be caused by radiation to the head or neck, or as a side effect of medications. In addition to the underlying disease as the cause, there are other causes for this condition. These include inadequate fluid consumption, sleeping with your mouth open, and weather conditions. The decreasing function of the salivary gland may or may not cause xerostomia to develop. This condition is most common in the elderly due to the frequent use of medication. It affects around 20% of the elderly worldwide. Xerostomia is associated with difficulty eating, speaking, swallowing, and wearing dentures. A dew patient suffering from this disease also suffers from dysgeusia, glossodynia, and other dental complications. To determine the function of the salivary gland, various diagnostic and imaging tests such as sialometry, salivary flow measurement, and sialography are recommended. If the salivary flow rate is less than 0.1 ml/minute, the condition is considered xerostomia.
The research study Xerostomia Treatments Market gives readers information on tactical business choices and strategic planning that affect and stabilize the growth prediction in the Xerostomia Treatments market. However, a few disruptive trends will have opposite and significant effects on the distribution among players and the growth of the Xerostomia Treatments market. To give further advice on why certain developments in the Xerostomia Treatments market would have a significant impact and specifically why these trends can be taken into account when determining the market's trajectory and industry participants' strategic plans.

•    The Xerostomia Treatments is growing at a CAGR of 18% during the forecasted period of 2023 to 2031
• Year-on-year growth for the market is 16%.
•   North America  dominated the market share in 2023
•    Based on type, the market is bifurcated into the Oral Rinses, Medications, Gels segment, which dominated the market share during the forecasted period
• Based on application, the market is segmented into Application Healthcare, Dentistry, Research as the fastest-growing segment.
• North America, LATAM, West Europe, Central & Eastern Europe, Northern Europe, Southern Europe, East Asia, Southeast Asia, South Asia, Central Asia, Oceania, MEA import/export in terms of K tons, K units, and metric tons will be provided if applicable, based on industry best practices.

Market Driver
The Xerostomia Treatments market is experiencing significant growth due to various factors.

• • Increasing Adoption of Chemotherapy and Radiotherapy in Cancer Treatment
• • The Rising Use of Prescribed Medications
• • Rising Consumption of Medications
• • Favorable Reimbursement Policies

Market Trend

The Xerostomia Treatments market is growing rapidly due to various factors.

• • Product Innovation
• • Natural Solutions

Opportunity

The Xerostomia Treatments has several opportunities, particularly in developing countries where industrialization is growing.

• • Growing Awareness and Supporting Patients with Xerostomia
• • Growing Healthcare Expenditure and Availability of Advanced Health Care Facilities

Challenge

The market for fluid power systems faces several obstacles despite its promising growth possibilities.

• • Regulatory Compliance
• • Cost of Treatment

 

• • Healthcare
• • Dentistry
• • Research

The companies featured in this profile were selected based on insights from primary experts, evaluating their market penetration, product offerings, and geographical reach. By targeting emerging markets, these companies aim to leverage new opportunities, enhance their competitive advantage, and drive revenue growth. This approach not only aligns with their overall business objectives but also positions them to respond effectively to the evolving demands of consumers in these regions. Several key players in the Xerostomia Treatments market are strategically focusing on expanding their operations in developing regions to capture a larger market share, particularly as the year-on-year growth rate for the market stands at 16%.

• • GlaxoSmithKline (United Kingdom)
• • Church and Dwight Co.
• • Inc. (United States)
• • Hikma Pharmaceuticals (United Kingdom)
• • Pendopharm (Canada)
• • Parnell Pharmaceuticals
• • Inc. (Australia)
• • Orahealth Corporation (United States)
• • Eisai Co.
• • Ltd (Japan)
• • EUSA Pharma (United Kingdom)
• • Colgate-Palmolive Company (United States)
• • Forward Science (United States)
• • Mission Pharmacal Company (United States)
• • OraPharma
• • Inc. (United States)

 

Need More Details on Market Players and Competitors?

Download Sample Report

The North America dominant region currently dominates the market share, fueled by increasing consumption, population growth, and sustained economic progress, which collectively enhance market demand. Conversely, the Europe is growing rapidly, driven by significant infrastructure investments, industrial expansion, and rising consumer demand.

• North America
• LATAM
• West Europe
• Central & Eastern Europe
• Northern Europe
• Southern Europe
• East Asia
• Southeast Asia
• South Asia
• Central Asia
• Oceania
• MEA

Report Features	Details
Base Year	2023
Based Year Market Size (2023)	1Billion
Historical Period	2019 to 2023
CAGR (2023 to 2031)	18%
Forecast Period	2026 to 2031
Forecasted Period Market Size (2031)	3Billion
Scope of the Report	By Type, By Application, By Region
Companies Covered	GlaxoSmithKline (United Kingdom), Church and Dwight Co., Inc. (United States), Hikma Pharmaceuticals (United Kingdom), Pendopharm (Canada), Parnell Pharmaceuticals, Inc. (Australia), Orahealth Corporation (United States), Eisai Co., Ltd (Japan), EUSA Pharma (United Kingdom), Colgate-Palmolive Company (United States), Forward Science (United States), Mission Pharmacal Company (United States), OraPharma, Inc. (United States)
Customization Scope	15% Free Customization Want to Buy Specific Sections of This Report? Sectional Purchase
Delivery Format	PDF and Excel through Email

 
The top-down approach begins with a broad theory or hypothesis and breaks it down into specific components for testing. This structured, deductive process involves developing a theory, creating hypotheses, collecting and analyzing data, and drawing conclusions. It is particularly useful when there is substantial theoretical knowledge, but it can be rigid and may overlook new phenomena. 
Conversely, the bottom-up approach starts with specific data or observations, from which broader generalizations and theories are developed. This inductive process involves collecting detailed data, analyzing it for patterns, developing hypotheses, formulating theories, and validating them with additional data. While this approach is flexible and encourages the discovery of new phenomena, it can be time-consuming and less structured. 

The healthcare sector is overseen by various regulatory bodies that ensure the safety, quality, and efficacy of health services and products. In the United States, the U.S. Department of Health and Human Services (HHS) plays a crucial role in protecting public health and providing essential human services. Within HHS, the Food and Drug Administration (FDA) regulates food, drugs, and medical devices, ensuring they meet safety and efficacy standards. The Centers for Disease Control and Prevention (CDC) focuses on disease control and prevention, conducting research, and providing health information to protect public health.